On March 3, 2025, Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focusing on targeting the CLEVER-1 receptor to reprogram myeloid cells for anti-tumor immunity in both hematological and solid tumors, announced a significant milestone. Their lead therapeutic candidate,
The pharmaceutical industry is abuzz with excitement over a new class of cancer drugs known as PD-1/VEGF inhibitors. These promising therapies, currently undergoing clinical trials, might leapfrog Merck & Co.’s highly successful cancer immunotherapy, Keytruda. The advent of these new drugs c
Parkinson's disease, a devastating neurodegenerative disorder, is characterized by the relentless loss of dopaminergic neurons, which leads to significant motor dysfunction and a decline in overall quality of life. Central to the pathology of PD are aggregates of alpha-synuclein protein and
The University of Manchester recently celebrated a significant milestone with the launch of the British Heart Foundation (BHF) Manchester Center of Research Excellence. Supported by a substantial £4 million grant from the BHF, this new center is set to advance world-class cardiovascular research
The collaborative effort between Protagonist Therapeutics and Takeda Pharmaceutical to develop rusfertide, an injectable drug aimed at treating polycythemia vera, has achieved a significant milestone. Polycythemia vera is a rare blood disorder marked by a proliferation of red blood cells that can
Antibody-drug conjugates (ADCs) are emerging as a groundbreaking approach in oncology, offering the potential to revolutionize cancer treatment through targeted and effective therapies. This innovation combines the precision of targeted antibodies with the potent cell-killing ability of
